Interface-formation processes in atomic layer deposition (ALD) of Al₂O₃ on InGaAs surfaces were investigated using on-line Auger electron spectroscopy. Al₂O₃ ALD was carried out by repeating a cycle of Al(CH₃)₃ (trimethylaluminum, TMA) adsorption and oxidation by H₂O. The first two ALD cycles increased the Al KLL signal, whereas they did not increase the O KLL signal. Al₂O₃ bulk-film growth started from the third cycle. These observations indicated that the Al₂O₃/InGaAs interface was formed by reduction of the surface oxides with TMA. In order to investigate the effect of surface-oxide reduction on metal-insulator-semiconductor (MIS) properties, capacitors and field-effect transistors (FETs) were fabricated by changing the TMA dosage during the interface formation stage. The frequency dispersion of the capacitance-voltage characteristics was reduced by employing a high TMA dosage. The high TMA dosage, however, induced fixed negative charges at the MIS interface and degraded channel mobility.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448916PMC
http://dx.doi.org/10.3390/ma5030404DOI Listing

Publication Analysis

Top Keywords

tma dosage
12
processes atomic
8
atomic layer
8
layer deposition
8
al₂o₃ ingaas
8
interface formation
8
kll signal
8
high tma
8
tma
5
initial processes
4

Similar Publications

Anion exchange membranes (AEMs) as a kind of important functional material are widely used in fuel cells. However, synthetic AEMs generally suffer from low conductivity, poor alkaline stability, and poor dimensional stability. Constructing efficient ion transport channels is widely regarded as one of the most effective strategies for developing AEMs with high conductivity and low swelling ratio.

View Article and Find Full Text PDF

Drug-induced thrombotic microangiopathy after adjuvant chemotherapy in malignant ovarian germ cell tumor: A case report and literature review.

Taiwan J Obstet Gynecol

November 2024

Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei City, Taiwan; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei City, Taiwan. Electronic address:

Article Synopsis
  • - A rare case of drug-induced thrombotic microangiopathy (DI-TMA) occurred in a 21-year-old woman after receiving BEP chemotherapy for a malignant ovarian germ cell tumor.
  • - The patient initially had a pelvic mass diagnosed as an endodermal sinus tumor and developed symptoms like anemia and kidney injury after chemotherapy, leading to a DI-TMA diagnosis.
  • - Following treatment with plasma exchange and discontinuation of chemotherapy, the patient remained disease-free for 17 months, highlighting the need for quick diagnosis and treatment of DI-TMA associated with chemotherapy.
View Article and Find Full Text PDF

REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.

J Diabetes Complications

December 2024

Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain; Hospital Universitario General de Villalba, Carretera de Alpedrete a Moralzarzal M-608 Km 41. CP2 8400 Collado Villalba, Madrid, Spain; Hospital Universitario Rey Juan Carlos, Gladiolo s/n, CP 28933 Móstoles, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez-Díaz (IIS-FJD), Universidad Autónoma de Madrid (UAM), Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain.

Objective: To evaluate the efficacy of switching to once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) who were previously treated with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in a real-world setting in Spain.

Methods: The REAL Life study of SEMaglutide in Patients with Type 2 diabetes in Spain (REALSEM-SP) was conducted in four endocrinology departments in Madrid, Spain. Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.

View Article and Find Full Text PDF

[Not Available].

Cancer Rep (Hoboken)

October 2024

Haematology Unit, Careggi University Hospital, Florence, Italy.

Article Synopsis
  • - Thrombotic microangiopathy (TMA) is a serious syndrome linked to microangiopathic hemolytic anemia, low platelet count, and organ damage, particularly in the kidneys, and can be induced by the drug carfilzomib, used for treating multiple myeloma.
  • - The report details two cases of multiple myeloma patients who developed TMA while on carfilzomib treatment; both patients saw significant improvements in kidney function and platelet count after receiving eculizumab.
  • - In a review of 91 patients receiving carfilzomib, a 2.2% incidence of drug-induced TMA was found, highlighting the need for prompt recognition and management, which includes
View Article and Find Full Text PDF

Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome.

Clin Med (Lond)

November 2024

Department of Internal Medicine, School of Medicine, University of Zagreb, Šalata 3, 10000 Zagreb, Croatia; Department of Internal Medicine, Unit for Intensive Care, University Hospital 'Sveti Duh', Sveti Duh 64, Zagreb, Croatia.

Atypical haemolytic-uraemic syndrome (aHUS) is a rare disease associated with uncontrolled activation of the alternative complement pathway, leading to thrombotic microangiopathy (TMA). Early diagnosis and treatment with eculizumab, a monoclonal antibody targeting the complement component C5, are crucial to improve outcomes and prevent renal failure and mortality. Current recommendations include lifelong eculizumab therapy, yet this practice presents challenges including high treatment costs and increased infection risks from prolonged complement inhibition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!